NCT01340586View on ClinicalTrials.gov

Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on Hemodialysis

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
End Stage Renal Disease
Interventions
DRUG

Apixaban

Tablets, Oral, 5 mg, Once, 4 days

DRUG

Apixaban

Tablets, Oral, 5 mg, Twice, 15 days

Trial Locations (1)

Unknown

Orlando

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY